Compare FINV & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | IRWD |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 668.1M | 578.3M |
| IPO Year | 2017 | 2009 |
| Metric | FINV | IRWD |
|---|---|---|
| Price | $2.95 | $4.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $5.62 | ★ $6.10 |
| AVG Volume (30 Days) | 866.5K | ★ 1.6M |
| Earning Date | 11-18-2026 | 11-05-2026 |
| Dividend Yield | ★ 10.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.91 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $59.19 |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | ★ $3.87 | $7.00 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $2.80 | $2.31 |
| 52 Week High | $6.39 | $5.78 |
| Indicator | FINV | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 69.47 |
| Support Level | $2.89 | $3.99 |
| Resistance Level | $3.25 | $4.53 |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 59.02 | 95.75 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.